Trial Profile
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 09 Jul 2021 This trial has been completed in Italy (End Date: 11 Jul 2019) as per European Clinical Trials Database record.
- 23 Nov 2020 This trial has been completed in Netherlands (Global End Date: 11 Jul 2019) as per European Clinical Trials Database record.
- 11 Nov 2020 This trial has been completed in Portugal (Global End Date: 11 Jul 2019) as per European Clinical Trials Database record.